EVOX THERAPEUTICS LIMITED

• ⚠

  Material uncertainty over going concern

  Whilst the Company believes that further funds would be available before mid-2027, there can be no assurance that the Company will be able to generate funds on terms acceptable to the Company, in a timely basis, or at all, which would impact the Company's ability to continue as a going concern. The failure of the Company to obtain sufficient funds on acceptable terms when needed would have a material adverse effect on the Company's business, results of operations and financial condition. As such, these circumstances indicate the existence of a material uncertainty which may cast significant doubt about the Company's ability to continue as a going concern.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  -35.4%

  £21,442,498 → £13,844,128

• Net assets

  -43.4%

  £26,177,642 → £14,828,168

• Employees

  -31%

  58 → 40

• Operating profit

  +15.5%

  -£15,827,535 → -£13,376,717

• Profit before tax

  +12.1%

  -£14,718,381 → -£12,936,609

• Wages

  -43.6%

  £5,852,789 → £3,299,937

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Whilst the Company believes that further funds would be available before mid-2027, there can be no assurance that the Company will be able to generate funds on terms acceptable to the Company, in a timely basis, or at all, which would impact the Company's ability to continue as a going concern. The failure of the Company to obtain sufficient funds on acceptable terms when needed would have a material adverse effect on the Company's business, results of operations and financial condition. As such, these circumstances indicate the existence of a material uncertainty which may cast significant doubt about the Company's ability to continue as a going concern.”

Significant events

• “On 17 June 2024, the Company passed a special resolution approving the cancellation of £92.0m of the share premium account balance, with the amount so cancelled being credited to retained earnings in order to create distributable reserves for the subsequent share buyback described below.”
• “On 18 June 2024 the Company issued a buyback offering on its A Preferred and B Preferred shares to holders of such shares, at a discount of 50% on their original issue price. The process resulted in the Company repurchasing 121,325 A Preferred and 148,393 B Preferred shares which were then immediately cancelled.”
• “On the same date it was agreed that 84,589 Ordinary shares be converted to a new class of share, Ordinary Preferred.”
• “The Company issued 13,360 Ordinary shares of £0.01 during the year (2024: 50 Ordinary shares of £0.01) as a result of exercises from the Company share option scheme, see note 16.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

10

last 24 months

Officers appointed

2

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.